116 related articles for article (PubMed ID: 17675938)
1. [Therapeutic management of extensive bronchiolo-alveolar adenocarcinoma: chemotherapy or inhibitors of epidermal growth factor receptor tyrosine kinase?].
Cadranel J; Wislez M; Gounant V; Lavolé A; Antoine M; Milleron B
Rev Pneumol Clin; 2007 Jun; 63(3):147-54. PubMed ID: 17675938
[TBL] [Abstract][Full Text] [Related]
2. [Bronchiolar-alveolar carcinoma: From concept to innovative therapeutic strategies].
Wislez M; Lavolé A; Gounant V; Antoine M; Cadranel J
Presse Med; 2011 Apr; 40(4 Pt 1):389-97. PubMed ID: 21419590
[TBL] [Abstract][Full Text] [Related]
3. [EGFR tyrosine kinase inhibitors as a targeted therapy for bronchioloalveolar carcinoma of the lung: a case report of a clinically prompt and intensive response and literature review].
Svoboda M; Fabian P; Slabý O; Stanková M; Lakomý R; Nemecek R; Vyzula R
Klin Onkol; 2010; 23(4):224-30. PubMed ID: 20806820
[TBL] [Abstract][Full Text] [Related]
4. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
Miller VA; Riely GJ; Zakowski MF; Li AR; Patel JD; Heelan RT; Kris MG; Sandler AB; Carbone DP; Tsao A; Herbst RS; Heller G; Ladanyi M; Pao W; Johnson DH
J Clin Oncol; 2008 Mar; 26(9):1472-8. PubMed ID: 18349398
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of thoracic radiotherapy in patients with stage IIIB-IV epidermal growth factor receptor-mutant lung adenocarcinomas who received and responded to tyrosine kinase inhibitor treatment.
Yen YC; Hsu HL; Chang JH; Lin WC; Chang YC; Chang CL; Chow JM; Yuan KS; Wu ATH; Wu SY
Radiother Oncol; 2018 Oct; 129(1):52-60. PubMed ID: 29703499
[TBL] [Abstract][Full Text] [Related]
6. A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 ("Iressa").
Yano S; Kanematsu T; Miki T; Aono Y; Azuma M; Yamamoto A; Uehara H; Sone S
Cancer Sci; 2003 May; 94(5):453-8. PubMed ID: 12824893
[TBL] [Abstract][Full Text] [Related]
7. IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype.
Cadranel J; Quoix E; Baudrin L; Mourlanette P; Moro-Sibilot D; Morere JF; Souquet PJ; Soria JC; Morin F; Milleron B;
J Thorac Oncol; 2009 Sep; 4(9):1126-35. PubMed ID: 19574932
[TBL] [Abstract][Full Text] [Related]
8. Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma.
Kris MG; Giaccone G; Davies A; Fukuoka M; Garfield DH; Jassem J; Quoix EA; Sandler AB; Scagliotti GV; Van Meerbeeck JP; West H
J Thorac Oncol; 2006 Nov; 1(9 Suppl):S32-6. PubMed ID: 17409999
[TBL] [Abstract][Full Text] [Related]
9. Short-term gefitinib treatment brought about a long-term regression of bronchioloalveolar carcinoma without EGFR gene alterations: a case report.
Kijima T; Suzuki M; Ueda K; Minami S; Takeda Y; Goya S; Matsuoka H; Kumagai T; Yoshida M; Osaki T; Tachibana I; Yokota S; Kawase I
Oncol Res; 2007; 16(10):489-95. PubMed ID: 18196873
[TBL] [Abstract][Full Text] [Related]
10. Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation.
Taja-Chayeb L; Candelaria M; Brom R; Trejo-Becerril C; Meza F; Duenas-Gonzalez A
Lung Cancer; 2005 Nov; 50(2):259-63. PubMed ID: 16009451
[TBL] [Abstract][Full Text] [Related]
11. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
13. Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition.
Gandara DR; West H; Chansky K; Davies AM; Lau DH; Crowley J; Gumerlock PH; Hirsch FR; Franklin WA
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4205s-4209s. PubMed ID: 15217959
[TBL] [Abstract][Full Text] [Related]
14. Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa).
Milton DT; Kris MG; Gomez JE; Feinstein MB
Support Care Cancer; 2005 Jan; 13(1):70-2. PubMed ID: 15558327
[TBL] [Abstract][Full Text] [Related]
15. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
Li J; Zhang L; Zhu H; Pan W; Zhang N; Li Y; Yang M
DNA Cell Biol; 2018 Nov; 37(11):903-908. PubMed ID: 30277797
[TBL] [Abstract][Full Text] [Related]
16. Role of tyrosine kinase inhibitors in lung cancer.
Ansari J; Palmer DH; Rea DW; Hussain SA
Anticancer Agents Med Chem; 2009 Jun; 9(5):569-75. PubMed ID: 19519298
[TBL] [Abstract][Full Text] [Related]
17. Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib.
Vasile E; Tibaldi C; Chella A; Falcone A
J Thorac Oncol; 2008 Aug; 3(8):912-4. PubMed ID: 18670311
[TBL] [Abstract][Full Text] [Related]
18. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.
Hirsch FR; Varella-Garcia M; McCoy J; West H; Xavier AC; Gumerlock P; Bunn PA; Franklin WA; Crowley J; Gandara DR;
J Clin Oncol; 2005 Oct; 23(28):6838-45. PubMed ID: 15998906
[TBL] [Abstract][Full Text] [Related]
19. Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of bronchoalveolar carcinoma.
Patel JD
Clin Lung Cancer; 2004 Dec; 6 Suppl 1():S43-7. PubMed ID: 15638957
[TBL] [Abstract][Full Text] [Related]
20. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
Urata Y; Katakami N; Morita S; Kaji R; Yoshioka H; Seto T; Satouchi M; Iwamoto Y; Kanehara M; Fujimoto D; Ikeda N; Murakami H; Daga H; Oguri T; Goto I; Imamura F; Sugawara S; Saka H; Nogami N; Negoro S; Nakagawa K; Nakanishi Y
J Clin Oncol; 2016 Sep; 34(27):3248-57. PubMed ID: 27022112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
